Page Views: 105 Date Added: 01/24/2012 Last Updated: 01/24/2012 Expiry Date: 01/21/2022 Product/Service Details Colorectal Cancer Used in combination with IV fluorouracil-based chemotherapy for the first-line treatment of metastatic cancer of the colon or rectum.1 2 3 4 9 Analysis of pooled data suggests that use of bevacizumab in combination with fluorouracil and leucovorin is associated with prolonged survival.20 Has also been used in combination with oxaliplatin-containing regimens as first-line therapy for metastatic colorectal cancer†.38 Used in combination with IV fluorouracil-based chemotherapy for the second-line treatment of previously treated metastatic cancer of the colon or rectum.1 Interim analysis of data from one study indicated bevacizumab monotherapy† was associated with decreased survival compared with combination regimen consisting of fluorouracil, leucovorin, and oxaliplatin.1 Under investigation for use as adjuvant therapy following surgery for early-stage (i.e., stage I or II) colon cancer†.28 Non-small Cell Lung Cancer Used in combination with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC.1 10 11 33 d e Some clinicians consider combination of bevacizumab, carboplatin, and paclitaxel as a regimen of choice in the initial treatment of advanced NSCLC for eligible patients (i.e., performance status of 0–2, nonsquamous histology, no history of hemoptysis, absence of CNS metastases, and no concomitant anticoagulant therapy).27 Breast Cancer Used in combination with paclitaxel for initial treatment of metastatic HER2-negative breast cancer.1 Efficacy is based on prolonged progression-free survival; currently, no data available that demonstrate prolonged overall survival or amelioration of disease-related symptoms.1 In December 2010, after reviewing data from 4 clinical studies, FDA recommended to remove this indication from bevacizumab’s approved labeling because of lack of benefit on overall survival and unfavorable risk-benefit ratio.58 59 60 A public hearing was held on June 28–29, 2011.61 FDA’s final decision regarding approval status for this indication was pending at the time this drug monograph was finalized for publication. Bevacizumab is not indicated for use in the treatment of breast cancer that has progressed following the use of an anthracycline and taxane regimen for metastatic disease.1 Brain Tumors Used as a single agent for treatment of glioblastoma in patients whose disease has progressed following previous therapy.a Efficacy is based on increased objective response rate; currently, no data available that demonstrate prolonged overall survival or amelioration of disease-related symptoms.a Renal Cell Carcinoma Used in combination with interferon alfa for treatment of metastatic renal cell carcinoma.a Ovarian Cancer Under investigation for use in treatment of ovarian cancer†.26 Prostate Cancer Under investigation for use in treatment of prostate cancer†.23 24 Neovascular Age-related Macular Degeneration Has been used by intravitreal injection† in treatment of neovascular age-related macular degeneration†.34

Company Information (3S Corporation)

Company Profile: 3s Corporation is a bulk dealer and wholesaler for oncology products and anti-cancer drugs and injections from India. We supply large quantities of drugs and medications to major markets like UK, Europe, America and Africa.. >> More Website URL: http://www.bridgat.com/u37137